AHAyser Seda Hasdemir

Ayser Seda Hasdemir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ayser Seda Hasdemir has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Baseline Uric Acid-to-HDL Cholesterol Ratio Predicts Peritoneal Membrane Failure in Peritoneal Dialysis Patients

    by Veysel Baran Tomar, Omer Faruk Akcay, Asil Demirezen, Taha Enes Cetin, Ayser Seda Hasdemir, Cansu Dagasan, Ozant Helvacı, Kadriye Altok, Yasemin Erten

    Background/Objectives: Peritoneal membrane failure remains a major limitation of peritoneal dialysis (PD). Systemic inflammation contributes to membrane dysfunction, yet simple predictive biomarkers are lacking. The uric acid-to-HDL cholesterol ratio (UHR) represents a novel integrative marker of metabolic-inflammatory burden, but its association with membrane failure has not been investigated. Methods: This retrospective cohort study included adult patients who initiated PD between 1997 and 2023. Baseline UHR was calculated from laboratory measurements obtained within the first three months after PD initiation. The primary outcome was peritoneal membrane failure, defined as permanent transfer to hemodialysis due to ultrafiltration failure, inadequate solute clearance, or progressive membrane dysfunction. Receiver operating characteristic, Kaplan–Meier, and Cox regression analyses were used to evaluate the association between UHR and membrane failure. Results: Among 214 patients, 62 (29%) developed membrane failure during follow-up. Baseline UHR was significantly higher in patients with membrane failure. A UHR cut-off value of 14 was identified for risk stratification. In multivariable Cox regression analysis, UHR >14 was independently associated with an increased risk of membrane failure (hazard ratio 1.836, 95% CI 1.040–3.241). A history of kidney transplantation prior to PD initiation also emerged as a strong independent predictor of membrane failure. Conclusions: Elevated baseline UHR is independently associated with peritoneal membrane failure in PD patients. As a simple and readily available biomarker, UHR may support early risk stratification and individualized management. Prospective multicenter studies are warranted to validate these findings.


  • Open Access

    Baseline Uric Acid–to–HDL Cholesterol Ratio Predicts Peritoneal Membrane–Related Technical Failure in Peritoneal Dialysis Patients

    by Veysel Baran Tomar, Omer Faruk Akcay, Asil Demirezen, Taha Enes Cetin, Ayser Seda Hasdemir, Cansu Dagasan, Ozant Helvacı, Kadriye Altok, Yasemin Erten

    Peritoneal membrane–related technical failure remains a major limitation of peritoneal dialysis (PD), yet simple predictive biomarkers are lacking. The uric acid–to–HDL cholesterol ratio (UHR) is an integrative marker of metabolic-inflammatory burden. This retrospective cohort study included 214 adult patients who initiated PD between 1997-2025 at a tertiary center. Baseline UHR was calculated from laboratory measurements obtained within three months after PD initiation. The primary outcome was peritoneal membrane–related technical failure, defined as permanent transfer to hemodialysis due to ultrafiltration failure, inadequate solute clearance, or progressive membrane dysfunction. Among 214 patients, 62 (29%) developed membrane failure during follow-up. A UHR cut-off value of 14 was identified by ROC analysis (AUC 0.644). In multivariable Cox regression, UHR >14 was independently associated with increased risk of membrane failure (HR 1.836, 95% CI 1.040–3.241, p = 0.036). A history of kidney transplantation prior to PD initiation also emerged as a strong independent predictor (HR 3.971, 95% CI 1.668–9.455, p = 0.002). Elevated baseline UHR is independently associated with peritoneal membrane–related technical failure. As a simple, inexpensive, and routinely available biomarker, UHR may support early risk stratification and individualized management in PD patients.